Recon: Drugmakers to increase Adderall output to combat U.S. shortage; EU’s proposed legislation may hurt pharma innovation

• Adderall makers agree to increase production: DEA (The Hill)
• Lawmakers ask FDA for information on US drug shortages (CIDRAP)
• Generics Review Data From US FDA Reveals Positives, Negatives For Industry (Pink Sheet)
• Watching The Clock Stop: US/EU Regulatory Review Time Parity In Sight, Study Suggests (Pink Sheet)
• Pharmacist Prescribing for BP Control Makes Economic Sense (Medpage Today)
• Medicare moves ahead with more price transparency requirements for hospitals (STAT)
• US CDC to expand surveillance of travelers for respiratory viruses (Reuters)
• ‘Resilient’ Trials: US FDA Wants To Apply COVID Lessons In Trial Design (MedTech Insight)

• EU proposal may accelerate pharma innovation decline, industry group says (Reuters)
• European Parliament Explains ‘Vanishing’ Study On Balancing Access & Innovation In EU (Pink Sheet)
• EU Decision Time For GSK’s Rare Cancer Drug Momelotinib & Others (Pink Sheet)
• Novo Nordisk warns EU that new rules will push it to expand faster in US (The Financial Times)
• Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines (STAT)
• England's young cystic fibrosis patients face new treatment worry (Reuters)
• BioNTech cuts 2023 revenue target on reduced prospects for vaccine (Reuters)

• Astellas shows enough data for eye treatment to support expanded use, but still lags competitor (STAT)
• XBI biotech index rises, giving investors a shred of hope (STAT)
• Bristol Myers buys Orum's blood cancer therapy for up to $180 mln (Reuters)
• The Endpoints Slack interview: Roivant CEO Matt Gline on playing moneyball in pharma, Vivek and politics, and the $7B Roche deal (Endpoints)
• CARGO Therapeutics eyes one of 2023's largest IPOs in a dull year for listings (Endpoints)
• MoonLake’s stock falls more than 20% despite mid-stage success in psoriatic arthritis (Endpoints)
• Zentalis shakes up PhIII plans in ovarian cancer; Halozyme's deal with Acumen; Korro's $117M private placement (Endpoints)
• Cellares to produce Cabaletta’s autoimmune CAR-T candidate (Endpoints)
• BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance (Endpoints)
• RAPT Therapeutics bolsters partner search with PhII data on small molecule-Keytruda combo (Endpoints)
• AstraZeneca, Eledon and Alpine spell out kidney program successes: ASN roundup (Endpoints)
• Starton Therapeutics scraps SPAC deal that would have taken it public, brought in $50M (Endpoints)

• Notified Body Designations Under The MDR Hit The 40 Mark With New Turkish Designation (MedTech Insight)
• Twists And Turns Ahead For Medtech In Europe As AI Dominates October Regulatory Debates (MedTech Insight)
• In experiment, electrical stimulation of the spinal cord helps a patient with Parkinson’s to walk (STAT)
• 5 companies to watch as medtech earnings wind down (MedTech Dive)
• Siemens Healthineers to lay off 300 workers, move some manufacturing to Ireland (MedTech Dive)
• J&J links radiofrequency catheter to improved quality of life in atrial fibrillation study (MedTech Dive)
• Stryker in ‘sprint back to 2019’ as procedures grow and supply chain, staffing pressures improve (MedTech Dive)
• Inari Medical to buy limb-saving device maker LimFlow for up to $415M (MedTech Dive)
• Penumbra touts benefits of vacuum thrombectomy for PE in late-breaking data (MedTech Dive)

• California Low-Cost Insulin Faces Delays After Price-Cap Veto (Bloomberg Law)
• Gilead Wants Ex-Executive to Repay Millions for Insider Probe (Bloomberg Law)
• Latest data shows millions of eligible Americans have been disenrolled from Medicaid (STAT)
• Exclusive: Cigna explores shedding Medicare Advantage business -sources (Reuters)
• News We’re Watching: AGs Push For Pulse Ox Warnings. VP Harris Announces AI Initiatives; FDA Looks At Digital Health And Diabetes (MedTech Insight)